Modus Therapeutics publishes year-end report for 2021

STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2021. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the year-end report.

John Öhd, Modus Therapeutics' CEO, commented:  "This has been a transformative year for Modus, as we set out and executed on our new strategy to focus sevuparin development on sepsis, launched our oversubscribed IPO on First North, and rapidly progressed into a Phase 1b clinical trial that evaluates sevuparin during LPS challenge. In 2022 we are looking forward to seeing results from the ongoing trial and advancing into the planned Phase 2 sepsis patient trial. We’d like to thank all our colleagues, collaborators and investors as we look forward to what promises to be an exciting 2022."

The fourth quarter in figures

• The loss after tax amounted to TSEK 12 289 (1 019).
• The loss per share amounted to SEK 0,76 (0,12).
• The cash flow from current operations was negative in the amount of TSEK 8 387 (1 107).

The full year in figures

• The loss after tax amounted to TSEK 20 691 (6 019).
• The loss per share amounted to SEK 1,67 (1,12).
• The cash flow from current operations was negative in the amount of TSEK 16 078 (7 231).
• Cash and cash equivalents amounted to TSEK 20 648 (7 345).

Important events during the quarter

• Symbiosis Pharmaceutical Services starts producing sevuparin for Modus' future clinical development in sepsis/septic shock.
• Modus Therapeutics engages Lago Kapital as a liquidity guarantor.
• Modus Therapeutics Receives Regulatory Approval to Start Phase 1b Clinical LPS Challenge Study with Sevuparin in the Netherlands.
• First subject was dosed in the Phase 1b Clinical LPS Challenge Study.

Important events after the end of the period

No event to report.

The year-end report will also be presented at an investor webcast today February 22th 2022 at 11:30CET. The webcast can be accessed via the following link  https://youtu.be/NRShQTmQ76o or via the Modus website.

This information is such information that Modus Therapeutics Holding AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on February 22, 2022.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.